Atherion Bioresearch Announces Agreement with NoyMed CRO

DUBLIN, Ohio - Feb. 1, 2024 - PRLog -- DUBLIN, Ohio—Atherion Bioresearch, Inc. ("Atherion" or the "Company"), a full-service Clinical Research Organization ("CRO") company established by experienced drug development professionals and focused on helping its partners advance their pipelines, today announced the signing of a collaborative agreement with NoyMed CRO ("NoyMed"), an international clinical research organization offering advanced biometrics solutions to biotech, pharma, and medical device firms.

The companies establish a partnership through this agreement to offer their services to potential sponsors jointly or individually. Atherion and NoyMed can refer potential clients to each other in order to provide an expanded suite of services.

Atherion offers a wide array of drug development services and is differentiated from other CROs by its high level of engagement and industry experience. Atherion's founding members are drug development professionals who have successfully worked on the sponsor side to advance drugs and complete trials and have private and public pharmaceutical/biotechnology experience. Atherion's team knows the common pitfalls of outsourcing to CROs and strives instead to be a true partner in diagnostic and therapeutic pipeline advancement.

For over 10 years, NoyMed has been offering expert biostatistics, clinical data management (CDM), statistical programming, CDISC (Clinical Data Interchange Standards Consortium) conversion, medical writing, and pharmacovigilance solutions in almost all therapeutic areas. NoyMed operates internationally, with offices in the United States (Glendale, CA, Denver, CO) and Armenia (Yerevan, Vanadzor, Gyumri). Through leadership and extensive industry experience, NoyMed has driven 170+ clinical trials to success, focusing on enhancing project quality and minimizing project delivery timelines.

Atherion has selected NoyMed as one of its partners because of its expertise in biometrics, adding an essential set of data-driven tools to Atherion's service offerings. Atherion's strengths in medical imaging, radiopharmaceuticals and radiotherapeutics, and its deep regulatory experience expand NoyMed's arsenal.

Michael Rosol, PhD, Chief Executive Officer of Atherion, said, "I am delighted to announce this agreement with NoyMed that will help amplify the reach and accelerate the growth of both of our companies." Dr. Rosol continued, "This collaboration will help us further differentiate our organizations from the competition and enable us to bring additional high quality services to sponsors."

About Atherion
Atherion was established by a team of drug development professionals dedicated to helping clients efficiently advance their pipelines while avoiding the cost and timeline impact typically associated with working with contract research organizations. Atherion offers full-service clinical research services, tailored from our decades of industry experience, that enable clients to develop their technology towards successful commercialization. Please visit www.atherion-bioresearch.com.

About NoyMed CRO
NoyMed is a full-service CRO providing comprehensive clinical trial biometrics services to large pharmaceutical, biotechnology, and medical device sponsors, CROs and public organizations globally. NoyMed has a presence in key geographic regions with a globally decentralized management structure.